Drug Profile

Research programme: skeletal muscle activators - Cytokinetics

Alternative Names: CK 3672889; CK-1909178; CK-2066260

Latest Information Update: 16 Aug 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cytokinetics
Developer Astellas Pharma; Cytokinetics
Class Small molecules
Mechanism of Action Troponin-tropomyosin complex stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Muscle fatigue

Most Recent Events

16 Aug 2024 Preclinical development is ongoing in USA
08 Aug 2024 Cytokinetics plans phase I trials for Muscular dystrophies in 2024
03 Apr 2023 Cytokinetics and Astellas terminates Development and marketing agreement for skeletal muscle activators

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com